Clinical trial
A Phase I Study of the Wee 1 Kinase (Wee 1) Inhibitor AZD1775 in Combination With Radiotherapy and Cisplatin in Cervical, Upper Vaginal and Uterine Cancers (10041848, 10008224, 10008238, 10046888, 10014735)
NCT03345784 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Study of the Wee 1 Kinase (Wee 1) Inhibitor AZD1775 in Combination With Radiotherapy and Cisplatin in Cervical, Upper Vaginal and Uterine Cancers (10041848, 10008224, 10008238, 10046888, 10014735)
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- May 29, 2018
- Completion date
- May 10, 2022
- Enrollment
- 10 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.
cervical carcinoma, endometrioid adenocarcinoma, malignant female reproductive system neoplasm, recurrent cervical carcinoma, stage i uterine corpus cancer ajcc v7, stage i vaginal cancer ajcc v6 and v7, stage ia uterine corpus cancer ajcc v7, stage ib cervical cancer ajcc v6 and v7, stage ib uterine corpus cancer ajcc v7, stage ib2 cervical cancer ajcc v6 and v7, stage ii cervical cancer ajcc v7, stage ii uterine corpus cancer ajcc v7, stage ii vaginal cancer ajcc v6 and v7, stage iia cervical cancer ajcc v7, stage iib cervical cancer ajcc v6 and v7, stage iii cervical cancer ajcc v6 and v7, stage iii uterine corpus cancer ajcc v7, stage iii vaginal cancer ajcc v6 and v7, stage iiia cervical cancer ajcc v6 and v7, stage iiia uterine corpus cancer ajcc v7, stage iiib cervical cancer ajcc v6 and v7, stage iiib uterine corpus cancer ajcc v7, stage iiic uterine corpus cancer ajcc v7, vaginal carcinoma